or Try an Advanced Search...

    Technical Analysis for CYBN - Cybin Inc.

    Grade Last Price % Change Price Change
    C 10.95 -1.87% -0.21
    CYBN closed up 1.45 percent on Wednesday, November 20, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical CYBN trend table...
    Date Alert Name Type % Chg
    Boomer Buy Setup Bullish Swing Setup -1.87%
    Calm After Storm Range Contraction -1.87%
    NR7 Range Contraction -1.87%
    Narrow Range Bar Range Contraction -1.87%
    Inside Day Range Contraction -1.87%
    Gapped Up Strength -1.87%
    200 DMA Resistance Bearish -0.45%
    Crossed Above 20 DMA Bullish -0.45%
    Calm After Storm Range Contraction -0.45%
    Inside Day Range Contraction -0.45%
    Older End-of-Day Signals for CYBN ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance 2 minutes ago
    2x Volume Pace 2 minutes ago
    1.5x Volume Pace 2 minutes ago
    Down 3% 2 minutes ago
    Fell Below Previous Day's Low 2 minutes ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CYBN Chart by TradingView
    Basic chart:

    Profile

    Cybin Inc. Description

    Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Drugs Major Depressive Disorder Neurochemistry Psychedelic Drug

    Is CYBN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
    Nov 14 Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
    Nov 13 Cybin reports Q2 results
    Nov 13 Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
    Nov 6 Massachusetts psychedelics legalization initiative poised to fail
    Nov 3 Cybin Inc: Another High-Risk Psychedelics Play
    Oct 31 Cybin to Participate at the 2024 Milken Institute Future of Health Summit
    Oct 24 Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
    Oct 15 Cybin: Top Value Psychedelic Stock
    Oct 3 Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
    See more CYBN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 21.66
    52 Week Low 6.5
    Average Volume 347,569
    200-Day Moving Average 11.80
    50-Day Moving Average 9.92
    20-Day Moving Average 10.71
    10-Day Moving Average 11.17
    Average True Range 1.13
    RSI (14) 54.55
    ADX 34.18
    +DI 21.44
    -DI 13.83
    Chandelier Exit (Long, 3 ATRs) 10.48
    Chandelier Exit (Short, 3 ATRs) 13.02
    Upper Bollinger Bands 11.92
    Lower Bollinger Band 9.50
    Percent B (%b) 0.69
    BandWidth 22.65
    MACD Line 0.30
    MACD Signal Line 0.32
    MACD Histogram -0.0132
    Fundamentals Value
    Market Cap 4.53 Billion
    Num Shares 406 Million
    EPS -0.19
    Price-to-Earnings (P/E) Ratio -58.74
    Price-to-Sales 278.25
    Price-to-Book 3.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.99
    Resistance 3 (R3) 12.00 11.74 11.85
    Resistance 2 (R2) 11.74 11.53 11.73 11.80
    Resistance 1 (R1) 11.45 11.40 11.32 11.44 11.76
    Pivot Point 11.19 11.19 11.13 11.18 11.19
    Support 1 (S1) 10.90 10.98 10.77 10.89 10.56
    Support 2 (S2) 10.64 10.85 10.63 10.52
    Support 3 (S3) 10.35 10.64 10.47
    Support 4 (S4) 10.34